Skip to main content
In stock|Targeted Therapy

APG-2575 (Lisaftoclax)

Oncology TypeHematologic
Drug Class / MechanismBCL-2 Inhibitor
No Image
Description

APG-2575 (Lisaftoclax) is classified as a BCL-2 Inhibitor, sourced for use within our Targeted Therapy portfolio. Reach out to our team for full regulatory documentation, pricing, and current availability.

Therapeutic CategoryTargeted Therapy
Oncology TypeHematologic

Send Inquiry

Submit your details to get a formal quote for this product.

Step 1 of 3